EIDD-1931 is a COVID-19 inhibitor. EIDD-1931 has broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of EIDD-2801, an orally bioavailable NHC-prodrug (β-D-N4-hydroxycytidine-5'-isopropyl ester), improved pulmonary function, and reduced virus titer and body weight loss. Decreased MERS-CoV yields in vitro and in vivo were associated with increased transition mutation frequency in viral but not host cell RNA, supporting a mechanism of lethal mutagenesis in CoV. The potency of NHC/EIDD-2801 against multiple coronaviruses and oral bioavailability highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses.EIDD-1931 is an active metabolite of Molnupiravir (EIDD-2801).
MedKoo Cat#: 555756
Name: EIDD-1931
CAS#: 3258-02-4
Chemical Formula: C9H13N3O6
Exact Mass: 259.0804
Molecular Weight: 259.22
Elemental Analysis: C, 41.70; H, 5.06; N, 16.21; O, 37.03
| Solvent | mg/mL | mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 25.9 | 100.00 | |
| Water | 13.0 | 50.00 |
The following data is based on the product molecular weight 259.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
